Free Trial
OTCMKTS:JCRRF

JCR Pharmaceuticals (JCRRF) Stock Price, News & Analysis

JCR Pharmaceuticals logo
$4.57
0.00 (0.00%)
(As of 11/1/2024 ET)

About JCR Pharmaceuticals Stock (OTCMKTS:JCRRF)

Key Stats

Today's Range
$4.57
$4.57
50-Day Range
$4.30
$4.70
52-Week Range
$4.30
$4.70
Volume
N/A
Average Volume
200 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Receive JCRRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for JCR Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JCRRF Stock News Headlines

JCR Pharmaceuticals Completes Share Buyback for Strategic Growth
Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
JCR Pharmaceuticals Advances Gene Therapy Research
Modalis Therapeutics Corporation (4883.T)
See More Headlines

JCRRF Stock Analysis - Frequently Asked Questions

JCR Pharmaceuticals' stock was trading at $9.04 at the beginning of the year. Since then, JCRRF stock has decreased by 49.4% and is now trading at $4.57.
View the best growth stocks for 2024 here
.

Shares of JCRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
OTCMKTS:JCRRF
CIK
N/A
Fax
N/A
Employees
934
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (OTCMKTS:JCRRF) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners